|
| 37676819 | Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial. | J Natl Cancer Inst | 2024 |
| 38041475 | Adjuvant and salvage radiotherapy after neoadjuvant therapy and radical prostatectomy for high-risk localized prostate cancer. | Prostate | 2024 |
| 36256912 | Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984. | J Clin Oncol | 2023 |
| 38072760 | Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer. | Eur Urol Oncol | 2023 |
| 37733980 | Pretest Video Education Versus Genetic Counseling for Patients With Prostate Cancer: ProGen, A Multisite Randomized Controlled Trial. | JCO Oncol Pract | 2023 |
| 37290800 | SNMMI Consensus Statement on Patient Selection and Appropriate Use of <sup>177</sup>Lu-PSMA-617 Radionuclide Therapy. | J Nucl Med | 2023 |
| 37003085 | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. | Eur J Cancer | 2023 |
| 36996380 | Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial). | J Clin Oncol | 2023 |
| 36747644 | Ultrasensitive detection of circulating LINE-1 ORF1p as a specific multi-cancer biomarker. | bioRxiv | 2023 |
| 36763576 | Gaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the ADT & Metabolism Study): Protocol of a longitudinal, observational, cohort study. | PLoS One | 2023 |
| 36494221 | Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. | Eur Urol | 2023 |
| 36702553 | Clinical Implementation of <sup>177</sup>Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges. | J Nucl Med | 2023 |
| 36382533 | Differential responses to taxanes and PARP inhibitors in ATM-Â versus BRCA2-mutated metastatic castrate-resistant prostate cancer. | Prostate | 2023 |
| 35333400 | Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer. | Cancer | 2022 |
| 35440417 | Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11]. | Eur Urol | 2022 |
| 35439030 | Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers? | J Clin Oncol | 2022 |
| 35363308 | Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program. | Clin Cancer Res | 2022 |
| 35450732 | Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. | Eur Urol | 2022 |
| 36103646 | Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer. | JCO Precis Oncol | 2022 |
| 36082554 | Neoadjuvant Novel Hormonal Therapy Followed by Prostatectomy versus Up-Front Prostatectomy for High-Risk Prostate Cancer: A Comparative Analysis. | J Urol | 2022 |
| 36317634 | A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer. | J Clin Invest | 2022 |
| 35943799 | Patterns of structural variation define prostate cancer across disease states. | JCI Insight | 2022 |
| 34907080 | Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis. | Clin Cancer Res | 2022 |
| 35201622 | Genetic testing in prostate cancer management: Considerations informing primary care. | CA Cancer J Clin | 2022 |
| 35084050 | Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples. | Prostate | 2022 |
| 34965947 | The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial. | Clin Cancer Res | 2022 |
| 35082166 | Modeling Androgen Deprivation Therapy-Induced Prostate Cancer Dormancy and Its Clinical Implications. | Mol Cancer Res | 2022 |
| 32814846 | Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center. | Prostate Cancer Prostatic Dis | 2021 |
| 33683939 | Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer. | J Urol | 2021 |
| 33849963 | Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance. | Clin Cancer Res | 2021 |
| 33636278 | Enzalutamide With Radiation Therapy for Intermediate-Risk Prostate Cancer: A Phase 2 Study. | Int J Radiat Oncol Biol Phys | 2021 |
| 33502237 | Outcomes of Post-Neoadjuvant Intense Hormone Therapy and Surgery for High Risk Localized Prostate Cancer: Results of a Pooled Analysis of Contemporary Clinical Trials. | J Urol | 2021 |
| 33888356 | Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer. | Eur Urol | 2021 |
| 33497248 | Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update. | J Clin Oncol | 2021 |
| 34439209 | Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer. | Cancers (Basel) | 2021 |
| 34407973 | Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer. | Clin Cancer Res | 2021 |
| 34496240 | Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer. | Cell Rep | 2021 |
| 34778690 | Differential Activity of PARP Inhibitors in <i>BRCA1</i>- Versus <i>BRCA2</i>-Altered Metastatic Castration-Resistant Prostate Cancer. | JCO Precis Oncol | 2021 |
| 34197212 | Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. | J Clin Oncol | 2021 |
| 33208343 | Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer. | Clin Cancer Res | 2021 |
| 32959883 | The Impact of COVID-19 on Clinical Trial Execution at the Dana-Farber Cancer Institute. | J Natl Cancer Inst | 2021 |
| 31053766 | Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC). | Prostate Cancer Prostatic Dis | 2020 |
| 32001144 | Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. | Eur Urol | 2020 |
| 31862185 | Multiparametric MRI as a Biomarker of Response to Neoadjuvant Therapy for Localized Prostate Cancer-A Pilot Study. | Acad Radiol | 2020 |
| 32943461 | Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. | Clin Cancer Res | 2020 |
| 32679108 | Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. | Cancer Cell | 2020 |
| 32706639 | Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. | J Clin Oncol | 2020 |
| 32986533 | Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. | JCO Oncol Pract | 2020 |
| 32868381 | Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer. | Cancer Res | 2020 |
| 32273234 | Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Docetaxel. | Clin Genitourin Cancer | 2020 |